Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Conditions
Glucose Metabolism, Insulin Response, Amino Acid Metabolism
Interventions
Bacterial-Derived Protein, Whey Protein, Oral Dextrose
Dietary Supplement
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Denton, Texas
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 7 Months
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
Terminated Phase 2 Interventional Results available

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

NCT00859495
Conditions
Pleural Mesothelioma
Interventions
Doxorubicin, Cisplatin, Pemetrexed, Radiotherapy
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

NCT00923910
Conditions
Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL)
Interventions
WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4, KLH, WT1 Peptides, Endotoxin, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 74 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California